Black Americans are more likely to get pancreatic cancer than any other racial or ethnic group, according the National Cancer ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...

Scientists have developed a new molecule that can deliver powerful immune-activating treatment directly to cancer cells, ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Geneticist Nilabja Sikdar in Calcutta, with collaborators in Jadavpur University, Israel and the US, has found that patients ...

The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit organization dedicated to [...] READ MORE ...

Dr. Anandhan's research marks a significant step forward in the fight against pancreatic cancer, offering renewed hope for ...

Many cancer survivors struggle with muscle weakness, which can be so profound that they may have difficulties walking up a ...

PanTher Therapeutics today announced that the first patient has been treated with PTM-101 in a Phase 1b trial in pancreatic ductal adenocarcinoma.

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.